LMNB2 and hepatocellular carcinoma: Similarly, Atezolizumab mitigated tumor weight differences between the SPOP + LMNB2 + sh-NC and SPOP-M35L + LMNB2 + sh-NC groups, suggesting that SPOP mutations in HCC promote immune evasion partly through LMNB2 (Fig. 6B–D).